ONO-2017 for Seizures in Japanese Children and Teens
Part of Brain & nervous system clinical trials.
This study tests a new seizure medication called ONO-2017 in Japanese children and teenagers (ages 2–17) who have a specific type of seizure called POS that hasn't been controlled by current medicines. The goal is to see if this new drug is safe and helps reduce these seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are Japanese and between 2 and 17 years old
- You have been diagnosed with epilepsy with POS (a specific seizure type) for at least 6 months
- You've had at least one POS seizure in the past 4 weeks
- You are currently taking 1 to 3 seizure medications at steady doses for at least 2 months
- You have not been hospitalized for status epilepticus (prolonged or repeated seizures) in the past 3 months
- You have not had serious allergic reactions to seizure medicines in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (ONO-2017) for people with a type of epilepsy that causes whole-body seizures. It looks at whether adding this drug to your current seizure medicines can reduce how often those seizures happen.
This trial studies the safety of cenobamate for Japanese people who have partial onset seizures and have already finished a previous study of the same drug. It helps doctors learn more about long-term safety.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This trial tests whether a new seizure medicine (cenobamate) helps people whose seizures are caused by an overactive immune system. You would stay on your current treatments and add cenobamate to see if it reduces seizures.
This study looks at how cenobamate (a medication for seizures) affects healthcare use, like hospital visits or emergency room trips, in people with epilepsy whose seizures were not well-controlled by 2 to 5 other medicines. It is a real-world study, meaning it uses medical records to understand the impact.
This trial tests a new medication called NPT 2042 for people with a type of epilepsy that causes brief staring spells (absence seizures). It aims to see if the drug can reduce seizure frequency compared to a placebo (an inactive pill).
Hear when a new Partial Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.